All In Biotech

Drug Trial Radar · NCT03544723

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

A Phase 2, Multi-Center, Open Label Study to Evaluate Adenoviral p53 (Ad-p53) in Combination With Immune Checkpoint Inhibitor Therapy in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Tumors Approved for Anti-PD-1 or Anti-PD-L1 Therapy

Last checked: Nov 20, 2026Latest source record: Jun 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 1, 2018

Primary completion

Jun 30, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
MultiVir, Inc.Industry
Sponsor type
Industry
First posted
Jun 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers. Comparison will be made to historical data. General safety and efficacy using RECIST 1.1 and Immune-Related Response Criteria as well as ECOG performance will be utilized.

Conditions

  • Solid Tumor
  • Lymphoma

Interventions

  • Ad-p53Drug

    Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors. Immunotherapy. Gene Therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy endpoint is objective response rate (ORR)Time frame: Change in tumor size at the end of Cycle 2 (each cycle is 28 days)
  2. Safety assessments of adverse events per CTCAETime frame: Signed Informed Consent through 30 Days following the final treatment

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Robert H. Lurie Comprehensive Cancer Center | Northwestern University

    Chicago, Illinois · Recruiting

  • Rush University Cancer Center

    Chicago, Illinois · Recruiting

  • Morristown Medical Center

    Morristown, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.